Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Gastric HormonE BioMarkers of Preneoplastic Lesions (GEM) Study

NCT06085677 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT06085677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06085677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Gastric HormonE BioMarkers of Preneoplastic Lesions (GEM) Study
Lead sponsor
Imperial College London
Phase
Observational
Overall status
Unknown status
Start date
November 4, 2023
Completion date
September 2, 2024
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic atrophic gastritis, intestinal metaplasia, stomach neoplasm